お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
972292

抗感染症薬の世界市場(2020年~2027年)

Global Anti-Infective Drugs Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
抗感染症薬の世界市場(2020年~2027年)
出版日: 2020年11月21日
発行: DataM Intelligence
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の抗感染症薬市場の成長は、さまざまな感染症に対する意識の高まりによって推進されており、各国での感染症治療への償還の利用可能性が市場を牽引する上で重要な役割を果たしています。病院やプライマリケアクリニック数の増加も、抗感染症薬の需要を押し上げています。

一方で、多剤耐性医薬品が重要視されており、開発初期や臨床段階で失敗する企業が多いことによる研究開発の投資コストの高さが同市場の主な抑制要因として挙げられます。また、新興国市場における医療施設のリソース不足が市場成長の妨げとなっています。

当レポートは、世界の抗感染症薬市場について調査しており、市場機会、成長および抑制要因、製品タイプ・適応症・流通チャネル・地域別の市場分析、COVID-19パンデミックの影響、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別
  • 適応症別
  • 流通チャネル別
  • 地域別

第4章 市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 COVID-19の影響分析

  • 市場でのCovid-19の分析
  • Covid-19における価格力学
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 市場分析:製品タイプ

  • イントロダクション
  • 市場規模分析、および前年比成長分析
  • 市場魅力指数
    • 抗生物質
    • 抗ウイルス剤
    • 抗真菌剤
    • その他

第8章 市場分析:適応症別

  • イントロダクション
  • 市場規模分析、および前年比成長分析
  • 市場魅力指数
    • HIV感染
    • 肺炎
    • 呼吸器ウイルス感染症
    • 敗血症
    • 結核
    • その他の適応症

第9章 市場分析:流通チャネル別

  • イントロダクション
  • 市場規模分析、および前年比成長分析
  • 市場魅力指数
    • 病院薬局
    • 薬局
    • その他

第10章 市場分析:地域別

  • イントロダクション
  • 市場規模分析、および前年比成長分析
  • 市場魅力指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東とアフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市場位置付け/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Abbott Laboratories Limited
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Cipla Ltd.
  • Claris Life Sciences Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Panacea Biotech Ltd.
  • Novartis AG
  • Pfizer Ltd.
  • Ranbaxy Laboratories Ltd

第13章 主な考察

第14章 DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Market Overview

The global anti-infective drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

The anti-infective drugs are described as substances which prevent infectious agents or organisms from spreading. These are mostly communicable diseases spread from viruses, bacteria, fungi, and other organisms. Such infection causing micro-organisms include viruses, bacteria, fungi, viroid, and macro parasites. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by host. High prevalence and incidence rates of infectious diseases, especially viral infection, and newer drug introductions have resulted in increase in growth of global anti-infective drugs market. These factors are projected to drive demand for anti-infective drugs in the near future. There are several global players having well-established R&D with increased focus upon development of innovative drugs against multidrug resistant organisms.

Market Dynamics

The global anti-infective drugs market market growth is driven by the rise awareness among the population about various infectious diseases and the availability of reimbursements to infection treatment in various countries have played a significant role in driving the market. Rise in the number of hospitals and primary care clinics also boosts the demand for anti-infective drugs.

The increasing number of companies in the market, is expected to drive the growth in the forecast period

Anti-infectives drugs has been one of the major segment for many pharmaceutical companies from decades. Over the past two decades, the infection rate has grown significantly, particularly across the low and middle income countries. There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants. The primary driving factor for the growth of the market is increasing burden of several infectious diseases across developed and emerging markets such as different forms of influenza, diarrhea, hepatitis, and urinary tract infections, among others, which needs more attention from pharmaceutical and biotechnology companies.

Increase in hyperlipidemia cases expected to drive the market growth

Factors like increasing prevalence of infectious diseases and antimicrobial resistance to existing anti-infective agents are estimated to fuel the market growth. Moreover, escalating health-consciousness, about the availability of diagnostics for infectious diseases and avoidable risks associated with the early diagnosis are some of the factors projected to boost the growth.

Companies have recently launched a panel of FDA approved, modified antibiotics for their use in the treatment of acute bacterial skin and soft tissue infections; these drugs include Dalvance (Dalbavancin), Orbactiv (Oritavancin), Sivextro (Tedizolid), and Zevtera (Ceftobiprole). The high penetration of these anti-infective drugs due to their increased efficacy is expected to serve as a growth driver for the anti-infective agents market in the forecast period.

For instance, in 2016, the Food and Drug Administration (FDA) approved drugs, such as Descovy by Gilead, for the treatment of HIV-1 infection and Zepatier by Merck that targets chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.

High investment costs in R&D is likely to hinder the market growth

On the contrary, ome of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drug, where several companies product fail in the early-stage or clinical stage of development. Also, shortage of resources in healthcare facilities particularly in emerging markets, restricts the growth of this market.

COVID-19 Impact Analysis

COVID-19 was may have a complex long-term impact on anti-infective resistance. Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on anti-infective and on access to effective antimicrobials. However, the impact of covid-19 on the pharmaceutical industry is projected to be neutralized by certain factors including higher demand for currently marketed drugs including anti-infective.

Segment Analysis

By product type, the anti-infective drugs market is classified into antibiotics, antivirals, antifungals, other.

Antiviral segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

The antiviral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring the opportunities to expand in the lower and middle income countries, where epidemic infection rate is high. There is high diversity in patient pool which require long treatment procedures in hospital facilities as well as home care treatments.

Antiviral drugs refer to those prescription medicines that are capable of fighting against flu viruses in one's body. Antiviral drugs could include intravenous solutions, an inhaled powder, liquid, or pills. However, antiviral drugs cannot be purchased just over-the-counter, one would need a prescription for obtaining such drugs. The global antiviral drugs market is likely to observe considerable growth due to the rising incidences of viral infections.

Moreover, there has been observed a growing interest by government in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to imporve the distribution rate of antiviral agents to the needful in the required area of a country. Such factors are expected to boost the growth of antivirals segment over the forecast period.

On the basis of distribution channel, the Anti-Infective drugs market is classified into hospital pharmacy, pharmacy stores, others.

The hospital pharmacy are expected to dominate the Anti-Infective drugs market during the forecast period

The hospital pharmacies held the largest share in the Anti-Infective drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global Anti-Infective drugs market

North America region is dominating the global Anti-Infective drugs market accounted for the largest market share in 2019. The presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Moreover, high purchasing power for expensive drugs and the presence of favorable reimbursement policies are anticipated to further fuel the regional market during the forecast period.

Asia-Pacific is largest market in terms of share owing to the presence of generics companies and rising economic stability and increasing disposable income. Also, the growing geriatric population coupled with increased susceptibility to infections is expected to provide a potential growth platform in the forthcoming years. India is expected to exhibit high growth potential in terms of demand for anti-infective drugs market due to the presence of a large patient pool, governmental initiatives in undertaking various control programs, and rise in cost containment initiatives by drug manufacturers.

Competitive Landscape

The anti-infective drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd., and Sun Pharmaceutical Industries Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-infective drugs market globally.

Glenmark Pharmaceuticals Limited

Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Product Portfolio: The Company's portfolio comprised 164 products including of API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused in the areas of respiratory and dermatology.

Why Purchase the Report?

  • Visualize the composition of the Anti-Infective drugs market segmentation by product type, indication, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Anti-Infective drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Anti-Infective Drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global anti-infective drugs market report would provide an access to an approx. 61 market data table, 56 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Anti-Infective Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Anti-Infective Drugs Market - Market Definition and Overview

3. Global Anti-Infective Drugs Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Anti-Infective Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Targeted Diseases
      • 4.1.1.2. Growing Initiatives for the Awareness of Infectious Diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Emergence of Anti-infective Drugs Resistance and Side Effects Associated with Anti-infective drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Anti-Infective Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Anti-Infective Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Anti-Infective Drugs Market - By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Antibiotics *
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Antivirals
    • 7.3.3. Antifungals
    • 7.3.4. Other

8. Global Anti-Infective Drugs Market - By Indication

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.3. Market Attractiveness Index, By Route of Administration
    • 8.3.1. HIV Infection *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Pneumonia
    • 8.3.3. Respiratory Virus Infection
    • 8.3.4. Sepsis
    • 8.3.5. Tuberculosis
    • 8.3.6. Other Indications

9. Global Anti-Infective Drugs Market - By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospital Pharmacy *
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Pharmacy Stores
    • 9.3.3. Other

10. Global Anti-Infective Drugs Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6.
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. Germany
      • 10.5.7.2. U.K.
      • 10.5.7.3. France
      • 10.5.7.4. Italy
      • 10.5.7.5. Spain
      • 10.5.7.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Anti-Infective Drugs Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Anti-Infective Drugs Market- Company Profiles

  • 12.1. Abbott Laboratories Limited,*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cipla Ltd.
  • 12.3. Claris Life Sciences Ltd.
  • 12.4. Glenmark Pharmaceuticals Ltd.
  • 12.5. GlaxoSmithKline Pharmaceuticals Ltd.
  • 12.6. Lupin Ltd.
  • 12.7. Panacea Biotech Ltd.
  • 12.8. Novartis AG
  • 12.9. Pfizer Ltd.
  • 12.10. Ranbaxy Laboratories Ltd

LIST NOT EXHAUSTIVE

13. Global Anti-Infective Drugs Market - Premium Insights

14. Global Anti-Infective Drugs Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.